Introduction 146
Metabolic syndrome (MetS) describes a cluster of features including abdominal obesity, dyslipidemia, 147 hypertension and insulin resistance that are associated with an increased risk of developing type 2 148 diabetes, cardiovascular disease and death (1, 2) . Moreover, these risks are higher than those associated 149 with individual components of the syndrome (2). Up to one-quarter to one-third of the adult population 150 in Europe and the United States can be diagnosed with MetS (1-3), making it an important public 151 health target for disease prevention. 152
Both low total testosterone (T) and low sex hormone binding globulin (SHBG) have been associated 153 with an increased risk of MetS in men (4-9). However, serum concentrations of total and free T are 154 strongly linked to SHBG, especially in men with obesity (10). Whether the risk of MetS associated 155 with low T is independent of SHBG or vice versa, remains unclear. 156
Furthermore, T is converted to estradiol (E2) by the aromatase enzyme, which is highly expressed in 157 adipose tissue (11) . A recent experimental study showed that lowering E2 levels in healthy males 158 increased body fat, independent of T (12). Although both T and E2 are associated with variations in 159 body composition in men (12,13), the potential impact of E2 and the extent of aromatisation on the 160 risk for incident MetS has not been investigated prospectively. 161
162
Using data from the European Male Aging Study (EMAS), a prospective study of aging in European 163 men, we studied the association between baseline sex steroids (T and E2) and the risk of developing 164
MetS at follow-up and investigated if this association was independent of SHBG, body mass index 165 (BMI), insulin resistance and body fat measurements. We also assessed whether sex steroids were 166 associated with change in individual MetS components. 167
168

Methods 169
Subjects and study design 170
The prospective study design of EMAS has been described previously (14) . were lost to follow-up. 150 men were excluded because of known pituitary or testicular disease or 176 current drug use of medications that could affect pituitary or testicular function or sex steroid 177
clearance (e.g. GnRH agonists, testosterone, anticonvulsants). Ethical approval for the study was 178 acquired in accordance with local institutional requirements at each centre. All subjects gave written 179 informed consent. 180
181
Assessments 182
At both phases, participants completed a postal questionnaire that included information about general 183 health (response set: excellent, very good, good, fair or poor), smoking history (current, past or non-184 smoker) and frequency of alcohol consumption in the previous month (none, less than once a week, 1-185 2, 3-4, 5-6 or 7 days per week) (14) . Current prescription and non-prescription medication use was 186
recorded. 187
Height, weight and waist circumference were measured in a standing position. Body weight was 188 measured to the nearest 0.1 kg using an electronic scale (SECA UK Ltd, Birmingham, UK) and height 189 to the nearest 1 mm using a stadiometer (Leicester Height Measure, SECA UK Ltd). Waist 190 circumference was measured using anthropometric tape, and the median of three measurements was 191 used as the recorded value. Body mass index (BMI) was calculated as body weight (kilograms) 192 divided by the square of height (meters). Body fat percentage was calculated by the Siri equation, 193 based on a subject's average density (body mass divided by body volume) (15). Seated blood pressure 194 (Omron 500I, Omron Healthcare (UK) Ltd, Milton Keynes, UK) was recorded after a 5 min rest 195 period. Physical function was assessed via gait speed in a timed 50-feet walk (16). 196 Total T was measured by liquid chromatography-tandem mass spectrometry as described previously 201 (17). The lower limit of quantification (LOQ) was 0.25 nmol/l. The coefficients of variation were less 202 than 10% within runs and between runs. Measurement of total E2 was carried out by gas 203 chromatography-tandem mass spectrometry as described previously (18) . The LOQ for E2 was 7.34 204 pmol/l. The coefficients of variation were less than 5% within runs and between runs. The E2/T ratio, 205 a measure of aromatisation, was calculated by dividing total E2 concentration in nmol/L by total T 206 concentration in nmol/L. SHBG was measured by the Modular E170 platform 207 electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). Free T and E2 208 levels were calculated from total hormone levels, SHBG, and individual albumin concentrations by the 209
Vermeulen formula (19). 210
Albumin, glucose, cholesterol and triglyceride measurements were assessed at the local health care 211 facility. Insulin was assayed using quimioluminiscence (University of Santiago de Compostela). 212
Insulin resistance was calculated using the homeostasis model assessment of insulin resistance 213 (HOMA-IR) (20) . 214
215
Dual energy X-ray absorptiometry 216
In the Leuven and Manchester cohort, body composition at baseline was assessed by dual energy X-217 ray absorptiometry (DXA) (QDR 4500A Discovery scanner, Hologic Inc, Bedford, MA, USA), as 218 described elsewhere (21). Percentage body fat and trunk fat was calculated by dividing body fat mass 219 or trunk fat mass by total body mass, multiplied by 100. 220
221
Definition of the metabolic syndrome and its components
MetS when three or more of the following criteria were present: waist circumference ≥ 102 cm, 224 triglyceride level ≥ 1.7 mmol/l (150 mg/dl), HDL cholesterol levels < 1.03 mmol/l (40 mg/dl), blood 225 pressure ≥ 130/85 mmHg and a fasting glucose level ≥ 5.6 mmol/l (100 mg/dl). Subjects with missing data were excluded if MetS could not be determined with certainty. For 231 instance, a subject with four positive MetS criteria and one missing was classified as having MetS. 232
However, in a subject with two positive, two negative and one missing MetS criterion, the MetS status 233
could not be determined with certainty, and these subjects were excluded from the analysis. 234
235
Statistical analysis 236
Descriptive statistics were used to characterise subjects at baseline. Smoking status was categorised as 237 current versus never and ex-smokers (referent). Alcohol intake was stratified as less than four days per 238 week (referent) versus five or more days per week. General health was defined as poor/fair versus 239 good/very good/excellent (referent). To assess associations with decreasing sex steroid and SHBG 240 levels, these variables were multiplied by -1 and converted to standardised z-scores. Baseline total T, 241 free T and SHBG were also categorized into quintiles, with the middle quintile as referent. 242
Logistic regression analysis was used to determine associations between baseline sex steroids 243 (predictor) and incident MetS (outcome). Results were expressed as standardised odds ratios (OR) 244 with 95% confidence intervals (CI). The analysis was performed unadjusted, with adjustments for 245 age, study centre, smoking status, alcohol intake, physical activity and general health, and with 246 additional adjustments for SHBG or total T as indicated. As both insulin sensitivity and obesity can 247 influence T and SHBG levels, we subsequently adjusted for HOMA-IR, BMI and % body fat. We 248 further explored relationships between baseline sex steroids and individual components of MetS at 249 follow-up, using linear regression with adjustments for age, centre, alcohol intake, smoking status, 250 physical activity, general health and the baseline value of the individual component. To meet linear 251 regression assumptions, glucose and triglyceride levels were log transformed. Results were expressed 252 as standardised β-coefficients and 95% CI. P<0.05 was considered statistically significant. All 253 analyses were performed by using STATA version 13 (Stata corp. College station, TX, USA).
Results
257
Subject characteristics 258
In EMAS, MetS status at baseline and follow-up could be assessed in 2376 men. Of these men, 725 259 men with MetS at baseline were excluded from the analysis. 1651 men did not have MetS at baseline. 260
Of these, 289 (17.5%) developed MetS during the follow-up period. Baseline characteristics of the 261 1651 men without baseline MetS are presented in Table 1 . Their mean (SD) age was 58.5 (10.7) and 262 mean BMI was 26.3 kg/m² (3.3). 21.8% of the study subjects used antihypertensive drugs, 8.8% were 263 on statins and 2.0% were treated for diabetes. 264
Men with incident MetS had a higher weight, BMI, calculated body fat % and HOMA-IR. They had a 265 lower baseline self-reported health, compared to the men that did not develop MetS (Table 1) . Men 266 with incident MetS had lower levels of total and free T, a higher E2/T ratio and lower SHBG. Baseline 267 E2 levels were not significantly different between both groups. Already at baseline, subjects with 268 incident MetS had a higher waist circumference, systolic and diastolic blood pressure, fasting 269 triglyceride and glucose levels and lower HDL levels, compared to subject without MetS. Compared 270 to men who did not develop MetS, those with incident MetS were more often prescribed 271 antihypertensive drugs, statins and antidiabetic drugs at baseline (Table 1) . 272
273
Association between baseline sex steroids and incident MetS 274
Logistic regression analysis showed that lower total T and free T were associated with an increased 275 risk of incident MetS (OR=1.64 (CI 1.41-1.90) and OR=1.31 (CI 1.14-1.51) respectively). This 276 association persisted after adjustment for age, centre and lifestyle factors (alcohol intake, current 277 smoking status, physical activity and general health) (OR=1.72 (CI 1.48-2.01) for total T and OR=1.36 278 (CI 1.17-1.59) for free T) and for total T after further adjustment for SHBG (OR=1.43 (CI 1.16-1.76)). 279
Total E2 levels were not significantly associated with the risk of developing MetS (OR=1.04 (CI 0.91-280 1.19)). Adding SHBG to the model had no effect on this risk (OR=0.90 (CI 0.78-1.04)). A lower E2/T 281 ratio was associated with a decreased risk for incident MetS, independent of age, centre and lifestyle 282 factors and SHBG (OR=0.48 (CI 0.35-0.64)). SHBG itself was also independently associated withincident MetS (OR=1.78 (CI 1.48-2.13)). However, after adjustment for total T levels, the association 284 between SHBG and incident MetS was attenuated, but remained significant (OR=1.33 (CI 1.05-1.68)) 285
(Figure 1). 286
Further analysis after categorising sex steroid levels into quintiles, with the middle quintile as referent, 287
showed no evidence of a threshold effect (data not shown). Adding an interaction term for age (below 288 or above 60) or for BMI (below or above 30) had no significant effects, indicating that the sex-steroid 289 associated MetS risk does not vary in different age or BMI groups (data not shown). 290 291
Influence of BMI, body fat and insulin resistance on relation of sex steroids and incident MetS 292 -Insulin resistance 293
After further adjustment for HOMA-IR, total T, free T, E2/T ratio and SHBG remained strongly 294 associated with incident MetS (OR=1.64 (CI 1.40-1.91), OR=1.29 (CI 1.11-1.51), OR=0.41 (CI 0.31-295 0.54), OR=1.75 (CI 1.45-2.10)). Further the association between total E2 and incident MetS became 296 borderline significant (OR=1.37 (CI 1.00-1.88), p=0.049)) ( Table 2) . (Table 2) . 304
305
In the Manchester and Leuven cohorts, baseline DXA data are available in 713 men. In this subgroup, 306
MetS status could be determined in in 595 men at both study phases. Of these men, 402 (67.6%) had 307 no MetS at either time point. 59 (9.9%) men developed MetS during the study period. 308
In this subgroup, lower total T, free T and SHBG were also associated with an increased risk for 309 incident MetS after adjustment for age, centre and lifestyle factors (OR=2.28 (CI 1.60-3.25), OR=1.90 310 (CI 1.34-2.69) and OR=1.90 (CI 1.28-2.81) respectively), and a lower E2/T ratio showed an inverseassociation (OR=0.46 (CI 0.27-0.76)). Total E2 was not associated with MetS (OR=1.22 (CI 0.91-312
1.64)). 313
For total and free T and SHBG, the association with incident MetS remained after further adjusting for 314 % body fat (OR=2.25 (CI 1.52-3.31) for total T, OR=1.91 (CI 1.29-2.81) for free T and OR=1.87 (CI 315
and OR=0.68 (CI 0.37-1.24)). Total E2 was weakly associated with incident MetS when % body fat or 319 % trunk fat was added to the model (OR=1.49 (CI 1.06-2.10) and OR=1.50 (CI 1.06-2.12)). 320
321
Association between baseline sex steroids and SHBG and MetS components at follow-up 322
In the unadjusted model, lower total T, free T and SHBG levels at baseline were associated with a 323
higher waist circumference at follow-up ( (CI -0.04--0.01)). Lower total E2 levels were only associated with higher triglyceride levels (β=0.02
In this prospective study of middle-aged and elderly men, lower baseline serum T was prospectively 341 associated with an increased risk for incident MetS. Moreover, the association between low T and 342 incident MetS persisted after adjustments for SHBG, HOMA-IR, BMI and calculated body fat. In the 343
Leuven-Manchester subcohort, this association was also independent of DXA-measured body fat and 344 trunk fat. Total E2 levels were not associated with the development of MetS. A lower E2/T ratio, 345 reflecting lower aromatisation of T into E2, was associated with a reduced risk of developing MetS. 346
This association was also independent of SHBG, HOMA-IR and BMI, but not of body fat measured 347 by DXA. Lower baseline total and free T and SHBG levels were associated with higher triglyceride 348 and glucose levels and lower HDL levels at follow-up. A lower E2/T ratio was associated with lower 349 triglyceride and glucose levels and higher HDL levels. Total E2 was only associated with a higher 350 triglyceride level. suggesting that lower baseline total T levels were associated with a less favorable lipid profile (24) and 362 higher glucose levels (25). 363
364
Previous analysis of baseline EMAS cross-sectional data had revealed that obesity was strongly 365 associated with low T and low or inappropriately normal LH levels, reflecting dysfunction at thedysfunction in obese men may therefore account for the low total T, and both can be induced by 369 higher levels of proinflammatory cytokines and insulin resistance, associated with adiposity (26,27). 370
However, adjusting for SHBG and different measures of fat mass as well as insulin resistance did not 371 affect the association between low T and MetS. This suggests that factors directly associated with low 372 T may be important in driving the progression to metabolic syndrome in men, independent of SHBG, 373 insulin resistance and obesity. prospective data investigating the association between E2 and MetS. In men, circulating E2 levels are 383 in the picomolar range and chromatography/mass spectrometry methods are therefore needed for 384 accurate measurement of serum E2 (31). Around 60% of circulating E2 in men is produced by 385 aromatisation of T (11,32). Estrogens play an essential role in male physiology. They are not only 386 important for bone maintenance, but they also have metabolic effects on carbohydrate and lipid 387 metabolism and fat distribution, not only in humans, but also in rodents. Estrogen receptor α 388 disruption, both in the presence or absence of androgen receptor, increases fat mass in male mice 389 (33,34). An absolute lack of E2, such as in men with congenital aromatase or estrogen receptor alpha 390 deficiency and in aromatase knockout mice, has also been associated with the development of several 391
MetS components such as truncal obesity, lipid disorders and insulin resistance (35). Moreover, a 392 recent study showed that experimentally-induced short-term estrogen deficiency resulted in an 393 increase in body fat in men (12). In our study, we found no association between baseline E2 levels and 394 incident MetS. Our results are in line with a cross-sectional study in middle-aged and elderly men (36)chromatography-tandem mass spectrometry. In other recent cross-sectional studies, both higher (37) 397 and lower (38) E2 levels, measured by radioimmunoassay (which may be unreliable), have been 398 associated with MetS in men. 399
The activity of the aromatase enzyme can be upregulated by multiple factors, such as inflammatory 400 adipocytokines, insulin and free fatty acids. This results in increased intracellular E2 levels that can 401 activate the estrogen receptor (27,39). Circulating E2 levels may not reflect the local actions of E2 in 402 target tissues. The E2/T ratio may therefore be a better indicator of aromatisation than a single 403 measurement of circulating E2. A positive correlation between the E2/T ratio and BMI as well as 404 different measures of body fat has been reported, but these associations were not independent of 405 visceral adipose tissue (40). More recently, cross-sectional data from the Boston Area Community 406
Health/Bone survey also showed a positive association between the E2/T ratio and body composition, 407 measured anthropometrically and by DXA (13). In a recent short-term intervention study, 408 administration of an aromatase inhibitor with T replacement to GnRH analog-treated men, thereby 409 lowering E2/T ratio, resulted in an increase of body fat (12). Interestingly, in our study, a lower E2/T 410 ratio, reflecting lower aromatisation of T into E2, was strongly associated with a reduced risk for 411 incident MetS. However, this association was not independent of DXA-measured body fat, indicating 412 that changes in body composition may modify the association between the estrogen-androgen balance 413 and MetS. This may account for the discrepancy between our findings and those from short-term 414 aromatase inhibition. Moreover, administration of an aromatase inhibitor to young men results in 415 virtually undetectable, non-physiologic E2 levels, which are clearly different from the E2 levels 416 observed in our study population of middle-aged and older men. 417
418
Our study has several strengths. It is a large, population based study and standardised methods in 419 design and analysis were used. As recommended by the Endocrine Society (41), serum T and E2 420 measurements were done by respectively liquid or gas chromatography-tandem mass spectrometry, 421 giving more accurate results as compared to other population studies that have used immunoassaysinsulin resistance and body composition, these results add insights into the specific effects of sex 425 hormones independent of adiposity. 426
There are some limitations which need to be considered. Our results were based on an analysis of 427 responders to both baseline and follow up phases and in whom data on MetS were available. Therefore 428 caution is needed in interpreting data on incidence of MetS. Any response or loss to follow-up bias is 429 though unlikely to influence our findings as these were based on an internal comparison of responders. 430
Finally, our data were based on analysis of a relatively healthy proportion of European men. 431
Extrapolating these data to other populations should be done with care. 432
433
In conclusion, low T but not E2 levels in men may be regarded as a biomarker or risk predictor for 434 
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